These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2083188)

  • 21. [Complete regression of pulmonary metastasis from renal cell carcinoma following treatment with UFT].
    Masuda F; Suzuki M; Nakada J; Mochizuki A; Kondo I
    Nihon Hinyokika Gakkai Zasshi; 1987 Jul; 78(7):1266-9. PubMed ID: 3119908
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
    Zaniboni A; Simoncini E; Marpicati P; Montini E; Ferrari V; Marini G
    J Chemother; 1989 Oct; 1(5):350-1. PubMed ID: 2585035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of coumarin and cimetidine in metastatic renal cell carcinoma.
    Venook AP; Davenport Y; Tseng A
    J Clin Oncol; 1989 Mar; 7(3):402-3. PubMed ID: 2918335
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Complete remission of lung metastasis of renal cell carcinoma by (UFT) therapy].
    Sugawara T; Sakuramoto T; Fukushima S
    Hinyokika Kiyo; 1987 Aug; 33(8):1232-5. PubMed ID: 3122543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study.
    Inhorn L; Williams SD; Nattam S; Stephens D
    Am J Clin Oncol; 1992 Apr; 15(2):157-9. PubMed ID: 1553905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma.
    Guimaraes JL; Ghosn M; Ostronoff M; Azab M; Theodore C; Droz JP
    Cancer Invest; 1990; 8(6):623-4. PubMed ID: 2292054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
    Yagoda A; Abi-Rached B; Petrylak D
    Semin Oncol; 1995 Feb; 22(1):42-60. PubMed ID: 7855619
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 30. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
    Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
    [No Abstract]   [Full Text] [Related]  

  • 31. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
    Stoter G; Shiloni E; Gundersen S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():59-63. PubMed ID: 2788507
    [No Abstract]   [Full Text] [Related]  

  • 33. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
    Ruangkanchanasetr P; Kanjanapayak B; Jungmeechoke K
    Nephrology (Carlton); 2011 Jan; 16(1):118-9. PubMed ID: 21175989
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331
    [No Abstract]   [Full Text] [Related]  

  • 38. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 39. [Complete regression of pulmonary metastases from renal cell carcinoma induced by medroxyprogesterone and streptococcal preparation: a case presentation].
    Nagakura K; Takao M; Matsuzaki S; Ieda K
    Nihon Hinyokika Gakkai Zasshi; 1985 Dec; 76(12):1909-13. PubMed ID: 2940397
    [No Abstract]   [Full Text] [Related]  

  • 40. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.